Tejas Patil
@TejasPatilMD
Thoracic oncologist @CUCancerCenter, via @Penn & @KeckMedUSC | Interests in #biomarkers & #PrecisionOncology in #lungcancer | Classical pianist on the side
In pts with #EGFR #NSCLC, what is the value of continuing osimertinib with platinum-pemetrexed after progression vs stopping osimertinib & switching to platinum pemetrexed? I’m proud to present our multi-center, retrospective, international series published in @LungCancer 🧵
3. In a study where there are limited treatment options and survival with SOC is the order of months, a phase 3 trial that uses ORR or PFS as a primary endpoint is unacceptable. 4. Why is it still acceptable in 2025 to have phase 3 trials that do not permit cross over when OS is…
Two opinions that to my surprise are either unpopular or not widely held: 1. The control arm of a randomised trial should be best standard of care. 2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.
Predictable that these 3G EGFR TKIs are comparable. No surprises here. What I find most interesting with lazertinib is lower QTc and cardiomyopathy, as this does occasionally come up with osimertinib. @EGFRResisters @lcsmchat @OncoAlert @medicalwatchBC @OPENoncology @LungCancerRx
OA02.05 - Lazertinib vs Osimertinib in 1L EGFR+ aNSCLC: Exploratory analysis from MARIPOSA Comparable efficacy between lazertinib and os including ORR, PFS, OS Some differences in AE profiles. Numerically less QT prolongation and cardiomyopathy with lazertinib. #WCLC24
NEOIPOWER (@LungCaJournal): In resectable stage II–IIIB #EGFR+ NSCLC, neoadjuvant icotinib + chemo led to an ORR of 83.3%, but MPR was just 6.7% with no pCR. Adds to growing evidence of limited pathologic response w/ TKIs in this setting.🚨 @OncoAlert lungcancerjournal.info/article/S0169-…
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures @Nature @SwantonLab @QuezadaLab @NickyMcGranahan @JL_Reading @drmaiseb nature.com/articles/s4158…
A strong start to Day 2 of @OncLive Bridging The Gap 2025 with a high-impact session on early-stage NSCLC chaired by @DrRaviSalgia. Featuring talks and discussions from @jdoningtonmd, @TejasPatilMD, @ChristineBestv1, @BalazsHalmosMD, @HwakeleeMD, and @lungoncdoc. #BTGLung2025…
Magnitude of OS benefit for FLAURA2 will be relevant here. Since crossover was not mandated per study design, the next question should be what did the control arm receive and when? IMO - the central clinical, real world, question that FLAURA2 is trying to answer is whether…
News From Industry/ FLAURA2 Update Source AstraZeneca buff.ly/IxqmQjH Long-term follow-up from the Phase III FLAURA2 trial confirms that combining osimertinib with platinum-based chemotherapy and pemetrexed significantly improves overall survival in patients with…
At NOSCM, @JuliaRotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled
🚨 New in immunoPET: A novel radiotracer, ⁶⁸Ga-NK224, non-invasive and dynamic way to track PD-L1: -Correlates with PD-L1 IHC in lung cancer -Detects intrapatient heterogeneity (SUVmax CV ~27.5%) -Monitors PD-L1 occupancy -Enables personalized IO dosing @OncoAlert #cancer…
In NSCLC & AGA we usually use the ⬆️ dose of targeted therapies despite no always correlation btw dose and efficacy or intracranial activity.In this review, we discuss these topics. Is time to redefine doses of TT as now applied across stages? doi.org/10.1016/j.ctrv…
I would also add: -Continued unrealistic inclusion/exclusion criteria. Excluding people with well-controlled HIV is simply discriminatory at this point. -Based on my personal experience: there is definitely less interest in studies involving randomization versus ph2 options